These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 20659612)

  • 1. Evaluating the cost of drugs used in the outpatient treatment of chronic pain.
    Vlainich R; Zucchi P; Issy AM; Sakata RK
    Rev Bras Anestesiol; 2010; 60(4):399-405. PubMed ID: 20659612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost analysis of adding pregabalin or gabapentin to the management of community-treated patients with peripheral neuropathic pain.
    Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Planas-Comes A
    J Eval Clin Pract; 2012 Dec; 18(6):1170-9. PubMed ID: 21883712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study.
    Pérez C; Navarro A; Saldaña MT; Masramón X; Rejas J
    Clin Ther; 2010 Jul; 32(7):1357-70. PubMed ID: 20678683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.
    Tarride JE; Gordon A; Vera-Llonch M; Dukes E; Rousseau C
    Clin Ther; 2006 Nov; 28(11):1922-34. PubMed ID: 17213013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost savings associated with early initiation of pregabalin in the management of peripheral neuropathic pain.
    Pérez C; Navarro A; Saldaña MT; Figueras-Balsells M; Muñoz-Tudurí M; Rejas J
    Clin J Pain; 2013 Jun; 29(6):471-7. PubMed ID: 23328322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in medication costs for patients with chronic nonmalignant pain completing a pain rehabilitation program: a prospective analysis of admission, discharge, and 6-month follow-up medication costs.
    Cunningham JL; Rome JD; Kerkvliet JL; Townsend CO
    Pain Med; 2009; 10(5):787-96. PubMed ID: 19302437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: a retrospective claims database analysis.
    Gore M; Tai KS; Sadosky A; Leslie D; Stacey BR
    J Med Econ; 2011; 14(4):497-507. PubMed ID: 21682606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pain treatment and its cost in old people with dementia: a descriptive analysis from the Registry of Dementias of Girona (ReDeGi).
    Calvó-Perxas L; López-Pousa S; Turró-Garriga O; de Eugenio R; Linares M; Fernández Mdel M; Castellanos M; Casas I; Turón-Estrada A; Casadevall T; Coromina J; Vilalta-Franch J; Garre-Olmo J;
    Int J Neurosci; 2013 May; 123(5):339-46. PubMed ID: 23270366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis.
    Navarro A; Saldaña MT; Pérez C; Masramón X; Rejas J
    Pain Pract; 2012 Jun; 12(5):382-93. PubMed ID: 22004531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence-based review of the pharmacoeconomics related to the management of chronic nonmalignant pain.
    Gupta A; Mehdi A; Duwell M; Sinha A
    J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):152-6. PubMed ID: 20504139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The payer side: patient outcomes and cost.
    Fish L; Nicholson BD
    Am J Ther; 2008; 15 Suppl 10():S20-2; discussion S22-3. PubMed ID: 19127125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-utility and cost-effectiveness analysis of an acute pain service.
    Stadler M; Schlander M; Braeckman M; Nguyen T; Boogaerts JG
    J Clin Anesth; 2004 May; 16(3):159-67. PubMed ID: 15217653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costing the components of pain management: analysis of Trans-Tasman Radiation Oncology Group trial (TROG 96.05): one versus five fractions for neuropathic bone pain.
    Pollicino CA; Turner SL; Roos DE; O'Brien PC
    Radiother Oncol; 2005 Sep; 76(3):264-9. PubMed ID: 16153729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use and costs of prescription medications and alternative treatments in patients with osteoarthritis and chronic low back pain in community-based settings.
    Gore M; Tai KS; Sadosky A; Leslie D; Stacey BR
    Pain Pract; 2012 Sep; 12(7):550-60. PubMed ID: 22304678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-utility study of the use of pregabalin added to usual care in refractory neuropathic pain patients in a Swedish setting.
    Prettyjohns M; Sandelin R; Lister S; Norrefalk JR
    J Med Econ; 2012; 15(6):1097-109. PubMed ID: 22712872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pregabalin in the treatment of refractory neck pain: cost and clinical evidence from medical practice in orthopedic surgery and rehabilitation clinics.
    Flórez-García M; Ceberio-Balda F; Morera-Domínguez C; Masramón X; Pérez M
    Pain Pract; 2011; 11(4):369-80. PubMed ID: 21199310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life, resource consumption and costs of spinal cord stimulation versus conventional medical management in neuropathic pain patients with failed back surgery syndrome (PROCESS trial).
    Manca A; Kumar K; Taylor RS; Jacques L; Eldabe S; Meglio M; Molet J; Thomson S; O'Callaghan J; Eisenberg E; Milbouw G; Buchser E; Fortini G; Richardson J; Taylor RJ; Goeree R; Sculpher MJ
    Eur J Pain; 2008 Nov; 12(8):1047-58. PubMed ID: 18359255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs.
    Dworkin RH; Malone DC; Panarites CJ; Armstrong EP; Pham SV
    J Pain; 2010 Apr; 11(4):360-8. PubMed ID: 19853529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-effectiveness analysis of the effect of pregabalin versus usual care in the treatment of refractory neuropathic pain in routine medical practice in Spain.
    de Salas-Cansado M; Pérez C; Saldaña MT; Navarro A; Rejas J
    Pain Med; 2012 May; 13(5):699-710. PubMed ID: 22594706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.